Subscribe

Japan Tissue Engineering Co., Ltd. (7774.T)

JPY673.00 +13.00 (+1.97%)
JP JPX Healthcare Biotechnology
Address 6-209-1 Miyakitadori 443-0022
Gamagori, JP
CEO Kazuto Yamada
Website jpte.co.jp
IPO 2007-12-28
ISIN JP3389610001

Explore sections of this company profile

Description

Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY673.00 +13.00 (+1.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
119.2K
Beta
0.60
Float Shares
11.05M
Free Float %
27.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+4.22% +9.96% +3.69% +4.75% +28.22% +5.64% +3.00% +15.30% -4.19% -58.41% +3.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
673.00
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
25.03
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -11.1% Q1'26: -10.1% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -187.6% Q1'26: -288.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -26.6% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -25.2% Q1'26: +2.1% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -29.9% Q1'26: +3.0% (vs Q1'25)
  • ✓
    Share dilution Biotechnology: -3.4%
    +0.0% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.58) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 673.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
1.32B
est: 1.30B (+1.7%)
1.43B
est: 1.42B (+0.6%)
2.14B
est: 2.00B (+6.8%)
2.27B
est: 2.35B (-3.3%)
2.36B
est: 2.45B (-3.6%)
2.31B
est: 2.67B (-13.5%)
2.26B
est: 2.91B (-22.5%)
2.10B
est: 3.40B (-38.2%)
2.03B
est: 2.13B (-4.6%)
2.51B
est: 2.83B (-11.2%)
2.46B
est: 2.94B (-16.5%)
3.89B
3.89B – 3.89B
+32.3% YoY
5.05B
5.05B – 5.05B
+29.7% YoY
6.21B
6.21B – 6.21B
+23.0% YoY
7.21B
7.21B – 7.21B
+16.1% YoY
EBITDA
-826.68M
est: -140.84M (-487.0%)
-807.21M
est: -154.11M (-423.8%)
425.34M
est: -216.60M (+296.4%)
327.71M
est: -254.45M (+228.8%)
-228.76M
est: -264.94M (+13.7%)
-111.03M
est: -289.16M (+61.6%)
-363.97M
est: -315.64M (-15.3%)
-373.21M
est: -368.57M (-1.3%)
-596.67M
est: -230.82M (-158.5%)
242.31M
est: 472.91M (-48.8%)
-124.74M
est: -355.88M (+65.0%)
-470.84M
-470.84M – -470.84M
-32.3% YoY
-610.61M
-610.61M – -610.61M
-29.7% YoY
-751.34M
-751.34M – -751.34M
-23.0% YoY
-872.47M
-872.47M – -872.47M
-16.1% YoY
EBIT
-916.55M
est: -218.51M (-319.4%)
-952.65M
est: -239.11M (-298.4%)
303.17M
est: -336.05M (+190.2%)
205.53M
est: -394.78M (+152.1%)
-348.52M
est: -411.06M (+15.2%)
-235.21M
est: -448.63M (+47.6%)
-466.86M
est: -489.72M (+4.7%)
-498.18M
est: -571.84M (+12.9%)
-728.12M
est: -358.11M (-103.3%)
144.51M
est: 366.50M (-60.6%)
-238.32M
est: -521.37M (+54.3%)
-689.79M
-689.79M – -689.79M
-32.3% YoY
-894.54M
-894.54M – -894.54M
-29.7% YoY
-1.10B
-1.10B – -1.10B
-23.0% YoY
-1.28B
-1.28B – -1.28B
-16.1% YoY
Net Income
-690.53M
est: -787.83M (+12.4%)
-681.54M
est: -651.79M (-4.6%)
276.24M
est: 267.59M (+3.2%)
227.89M
est: 281.15M (-18.9%)
-333.25M
est: -245.69M (-35.6%)
-287.10M
est: -95.43M (-200.8%)
-466.62M
est: -50.76M (-819.2%)
-497.89M
est: 158.38M (-414.4%)
-729.32M
est: -611.18M (-19.3%)
143.17M
est: 93.40M (+53.3%)
-255.30M
est: 142.13M (-279.6%)
588.84M
588.84M – 588.84M
+314.3% YoY
1.13B
1.13B – 1.13B
+92.4% YoY
1.67B
1.67B – 1.67B
+47.0% YoY
2.01B
2.01B – 2.01B
+20.7% YoY
SGA
958.19M
est: 650.26M (+47.4%)
1.05B
est: 711.53M (+47.7%)
822.52M
est: 1.00B (-17.7%)
863.52M
est: 1.17B (-26.5%)
979.24M
est: 1.22B (-19.9%)
1.01B
est: 1.34B (-24.3%)
1.08B
est: 1.46B (-25.7%)
1.12B
est: 1.70B (-34.1%)
1.22B
est: 1.07B (+14.5%)
1.06B
est: 1.42B (-25.4%)
1.14B
est: 1.52B (-24.7%)
2.01B
2.01B – 2.01B
+32.3% YoY
2.61B
2.61B – 2.61B
+29.7% YoY
3.21B
3.21B – 3.21B
+23.0% YoY
3.73B
3.73B – 3.73B
+16.1% YoY
EPS
-18.21
est: -19.40 (+6.1%)
-16.79
est: -16.05 (-4.6%)
6.81
est: 6.59 (+3.3%)
5.61
est: 6.92 (-19.0%)
-8.21
est: -6.05 (-35.7%)
-7.07
est: -2.35 (-200.9%)
-11.49
est: -1.25 (-819.2%)
-12.26
est: 3.90 (-414.4%)
-17.96
est: -15.05 (-19.3%)
3.53
est: 2.30 (+53.5%)
-6.29
est: 3.50 (-279.7%)
14.50
14.50 – 14.50
+314.3% YoY
27.90
27.90 – 27.90
+92.4% YoY
41.00
41.00 – 41.00
+47.0% YoY
49.50
49.50 – 49.50
+20.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-01 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-30 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-17 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-04-16 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-225.64M
OE per share TTM
-5.56
Owner's Yield
-0.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
68.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-2.60M
Shares Outstanding
40.61M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Kazuto Yamada Executive Officer, President, Chief Executive Officer & Director — male
Toshihiro Osuka Corporate Officer & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology